[Comment] Concordant phase 2 evidence and biological plausibility for rare tumours

Clear cell gynaecological tumours represent a paradigmatic example of the challenges of rare cancers, in which scarce clinical evidence contrasts with high unmet need, often affecting younger patients and raising concerns about equitable access to innovation. In The Lancet Oncology, Natalie Y L Ngoi and colleagues report the LARA (GCGS-OV4/APGOT-OV3) single-arm, multicentre, phase 2 trial of pembrolizumab plus lenvatinib in…